Ionis Pharmaceuticals IONS Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's cumulative cost basis?
- Ionis Pharmaceuticals (IONS) reported cumulative cost basis of $1.75B in Q1 2026.
- How has Ionis Pharmaceuticals's cumulative cost basis changed year-over-year?
- Ionis Pharmaceuticals's cumulative cost basis decreased by 8.6% year-over-year, from $1.91B to $1.75B.
- What is the long-term trend for Ionis Pharmaceuticals's cumulative cost basis?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's cumulative cost basis has grown at a 17.1% compound annual growth rate (CAGR), from $1.25B to $2.35B.